Flexivue Microlens

Rodman & Renshaw maintains a Buy rating on Presbia PLC (NASDAQ: LENS) after an interim data from the company showed that its corneal inlay product, the Flexivue Microlens, can achieve "significant improvement in uncorrected near vision acuity without loss of distance vision performance." "An...

Rodman & Renshaw has started Presbia PLC (NASDAQ: LENS) with a Buy rating and $14 price target, saying the company is "an unsung company with an intriguingly positioned device in the attractive ophthalmics domain." Presbia makes the Flexivue Microlens for presbyopia (nearsightedness). The...